Related Experiment Video

Updated: Apr 29, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.4K

Importance of Breast Cancer Subtype in the Development of Androgen Receptor Directed Therapy

Elgene Lim, Min Ni, Shiliang Cao

    Current Breast Cancer Reports
    |May 27, 2014
    PubMed

    Insights

    The androgen receptor (AR) is a promising therapeutic target for breast cancer. Research shows AR

    Area of Science:

    • Oncology
    • Endocrinology
    • Molecular Biology

    Background:

    • The androgen receptor (AR) is gaining attention as a therapeutic target in breast cancer.
    • Preclinical models reveal subtype-specific effects of AR expression on patient outcomes.
    • Advancements in AR-targeted therapies for prostate cancer are informing breast cancer treatment strategies.

    Purpose of the Study:

    • To review recent developments in preclinical studies of AR in breast cancer.
    • To summarize recent clinical trials targeting AR in breast cancer.
    • To emphasize the need for context and subtype specificity in AR-targeted breast cancer therapy.

    Main Methods:

    • Review of preclinical research on androgen receptor signaling in breast cancer.
    • Analysis of recent clinical trials investigating androgen receptor-targeted therapies for breast cancer.

    Main Results:

    • Preclinical studies highlight differential impacts of AR expression across breast cancer subtypes.
    • Emerging clinical trials are exploring novel AR-directed agents for breast cancer treatment.

    Conclusions:

    • Androgen receptor signaling is a context- and subtype-dependent therapeutic strategy in breast cancer.
    • Targeting the androgen receptor offers a promising avenue for specific breast cancer patient populations.
    • Further research and clinical trials are essential to optimize AR-targeted therapies for breast cancer.
    Keywords:
    Androgen receptorAndrogen receptor directed therapyBreast cancerBreast cancer subtype

    More Related Videos

    Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms08:46

    Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

    Published on: December 9, 2015

    12.8K
    Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer07:45

    Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer

    Published on: May 18, 2020

    6.2K

    Related Concept Videos

    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against...
    7.0K
    Mitogens and the Cell Cycle02:38

    Mitogens and the Cell Cycle

    Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
    6.3K
    Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

    Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

    Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
    81
    Combination Therapies and Personalized Medicine02:50

    Combination Therapies and Personalized Medicine

    Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
    The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
    4.9K
    mTOR Signaling and Cancer Progression03:03

    mTOR Signaling and Cancer Progression

    The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
    The mTOR pathway or the...
    3.6K
    Adrenergic Receptors: ɑ Subtype01:31

    Adrenergic Receptors: ɑ Subtype

    Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
    Adrenaline ≥ Noradrenaline >> Isoprenaline
    α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
    α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
    2.7K